



VIRAL CROUP

ALGORITHM: Outpatient/ED Management





ALGORITHM: Inpatient Management



*Acute COVID Pathway



TABLE OF CONTENTS

Algorithm: Outpatient/ED Management

Algorithm: Inpatient Management

Target Population

Prevention

Outpatient Telephone Triage

Clinical Management

Laboratory Studies | Imaging

Therapeutics

Disposition

Follow-Up | Discharge Instructions

Education

Etiology of Croup

References

Clinical Improvement Team

TARGET POPULATION

Inclusion Criteria

- Previously healthy
- First or repeat episode
- Age 6 months to 6 years
- Principle diagnoses: croup (laryngotracheitis)

Exclusion Criteria


- Suspicion of bacterial tracheitis, epiglottitis, upper-airway abscess (peritonsillar or retropharyngeal), or other serious bacterial infection
- Severe or life-threatening disease requiring PICU admission
- Chronic lung disease (bronchopulmonary dysplasia, cystic fibrosis, pulmonary artery hypertension)
- Known upper airway abnormalities (for example: laryngomalacia, tracheomalacia, subglottic stenosis)
- Recent airway instrumentation
- Foreign body aspiration or ingestion
- Neuromuscular disorder or hypotonia
- Allergic reaction
- Angioedema
- Active varicella or tuberculosis (TB)
- Congenital or acquired heart disease



PREVENTION

- Droplet precautions for all care settings; special respiratory precautions for confirmed COVID-19 cases
- Good hand washing
- Protect high risk patients from exposure
- · Minimize exposure to smoke

OUTPATIENT TELEPHONE TRIAGE



- Activate EMS (911): Severe difficulty breathing (struggling for breath, grunting noises with each breath, unable to speak or cry), blue lips or reduced level of consciousness.
- ED visit (immediate): Breathing heard across room, temperature greater than 105°F, excessive drooling, inability to lie flat without distress
 - Age less than 12 months- respiratory rate (RR) greater than 60, unable to sleep
 - Age greater than 12 months- RR greater than 40, difficulty breathing, not interactive
- Office visit same day: Worsening cough, some difficulty breathing, poor fluid intake, chronic or underlying illness including heart or lung disease
- Phone contact with primary care provider (PCP): barking cough, acting normally, good fluid intake

CLINICAL MANAGEMENT

Obtain History and perform physical exam
Evaluate hydration status
Distinguish croup from a more extensive or progressive process
Evaluate patient using Croup severity assessment

History:

- Obtain past medical history \ birth (hospitalization, intubation/mechanical ventilation), sick contacts
- Check immunization status: Haemophilus influenza type b (HIB), pneumococcal, tetanus, diphtheria. Important when considering epiglottitis or diphtherial croup



- Obtain all pertinent patient history, including onset and duration of symptoms including croup prodrome (rhinorrhea, sore throat, low grade fever, cough), timing of evidence of upper airway obstruction (hoarse voice, barking cough, audible stridor), and subglottic involvement (aphonia)
- Inquire regarding history of congenital or acquired heart disease, congenital or acquired subglottic stenosis, tracheomalacia, tracheal webs, choanal narrowing or atresia, micrognathia, macroglossia
- Check current medications and time and dose of last antipyretic and recent steroid use.

Clinical Symptoms of Croup:

- Symptoms increase at night and improve during day
 - Hoarse voice
 - Barking cough (often described as a "barking seal")
 - Stridor (variable, usually inspiratory)
- Respiratory distress (variable):
 - Retractions (suprasternal, intercostal)
 - Tachypnea
 - Tachycardia

Clinical Progress of Croup:

Day 1 to 3 Rhinorrhea
Sore throat
Low grade fever

Low grade fer Mild cough

Day 3 to 7

Onset symptoms of upper airway inflammation

Hoarseness Barking cough Stridor (variable)


Respiratory distress (variable)

Clinical symptoms that suggest Croup is not the diagnosis:

- Bacterial tracheitis should be considered if patients have a toxic appearance, poor response to racemic epinephrine, high fever, or have a rapid decomposition
- Hypoxemia is uncommon in croup and indicates severe disease, an alternate diagnosis, or lower respiratory tract disease

Differential Diagnosis:

- Distinguish croup from a more extensive or progressive process
- Conditions mimicking croup:





Monitoring:

Continuous cardiac/pulse oximetry monitoring only recommended for unstable patients and patients receiving 2 or more racemic epinephrine nebulizations within an hour due to risk of ventricular arrhythmias.

Severity Assessment:

Assess and record severity every 1-4 hours with vitals depending on patient's current severity and patient's location. (See algorithms)

Patients should be classified as mild, moderate or severe/life-threatening for each of the 5 categories including: stridor, retractions, vital signs, feeding and neurologic status.

	Mild	Moderate	Severe/life-threatening
Stridor	With activity or at rest	Biphasic with agitation. OR- Inspiratory at rest with moderate retractions AND at least 1 additional sign/symptom from the moderate categories below	Biphasic or absent due to poor respiratory effort
Retractions	Mild		Severe (intercostal, nasal flaring)
Vital signs	Normal oxygen saturation on room air, No tachypnea, No tachycardia	Mild tachypnea, Mild tachycardia	Hypoxemia or cyanosis, Marked tachycardia, or bradycardia
Feeding/talking	Able	Difficult	Unable
Neurologic status	Normal	Agitated OR tired, low tone	Abnormal, confused, drowsy

LABORATORY STUDIES | IMAGING

Radiographs and viral testing are not routinely indicated: Diagnostic tests are only indicated if they will change outcome. Croup is a clinical diagnosis and usually no testing is needed.

THERAPEUTICS

Routinely Indicated:

Corticosteroids

Dosing: Single dose

Dexamethasone

Dose: 0.6 mg/kg orally (preferred), IV

Frequency: Once

Maximum Dose: 16 mg

o Time to oral peak effect: 2 h

o Time to peak IV effect: 10 min

Duration of action: 24 to 72 h

Note: The taste of oral dexamethasone liquid is not well tolerated thus the preferred method of administration is a crushed dexamethasone tablet mixed with vehicle of choice. IM route is not recommended due to longer time to peak efficacy and erratic muscular absorption.



Nebulized Epinephrine

Racemic Epinephrine (1:1 mixture of δ & ϑ -isomers)

- Dose: 2.25% solution in 2.5mL NS via nebulizer over 15 minutes
 - For patients <5kg: 0.25 mL
 - For patients >/=5kg: 0.5mL
- Frequency: as needed based on severity (see algorithms)
- Duration of action: less than or equal to 2 hours

Note: If a patient requires 2 or more nebulizations within an hour, cardiac monitoring is recommended due to risk of ventricular arrhythmias.

The term 'rebound phenomenon' is a misnomer.

Epinephrine doesn't change the duration of croup.

It is safe to send children home from the ED, outpatient clinic or urgent care after receiving racemic epinephrine if they have been observed for a minimum of 2-3 hours post therapy.

Recommended in some patients:

In patients requiring ongoing repeated doses of racemic epinephrine after reaching full steroid effect consider additional evaluation for alternative diagnoses and/or a Rapid Response Team (RRT) evaluation.

- Consider ENT consult for laryngoscopy in patients with 2 or more episodes of croup AND one of the following:
 - History of intubation
 - Age less than 36 months
 - Prolonged or severe disease requiring inpatient management
- Consider evaluation for GERD and initiation of anti-reflux medications with prolonged or recurrent croup
- Consider evaluation and treatment for allergies

Nebulized Budesonide

- Dose: 2mg inhaled via nebulizer over 30 minutes
 - Equal efficacy to dexamethasone; expensive

Note: not for routine care. Consider in children with emesis or severe respiratory distress where IV access is unobtainable and the severity of symptoms makes IM dexamethasone not optimal due to its delayed onset.

Not Routinely Indicated:

Oxygen

- The presence of hypoxemia or intermittent desaturations is a sign of impending respiratory failure in croup and other central airway obstruction. Oxygen can be used to normalize SpO2, but further diagnostic evaluation and therapies may be needed. If hypoxemia is present, a blood gas may be useful to assess for hypercarbia.
- Croup can progress to laryngotracheobronchitis with lower airway involvement, which can cause hypoxemia. It is
 important to distinguish between severe croup and lower airway infection as this changes acuity and care
 management.

Other Therapies

- Mist: Humidified air with or without oxygen is not indicated
- Antitussive or decongestant medications are not indicated.
- Antibiotics play no role in viral croup



DISPOSITION

Begin discharge planning at time of initial presentation

- Assess caretaker ability to provide home care
- Assess home resources adequate to support care
- Confirm transportation and telephone
- Confirm follow-up PCP/designee in specified time frame
- Complete croup teaching
- Provide verbal and written instructions to caretakers
- Assure family awareness indications return
- Provide 24-hour contact number for PCP or designee
- Assure chart faxed to PCP or designee

Discharge Home

- Croup severity mild
- Minimal Stridor at rest (stridor with activity to be expected)
- Normal saturation on room air
- Able to talk and feed without difficulty
- Minimal or no retractions (mild suprasternal acceptable)
- 2-3 hours since racepinephrine

Note: Patients who have received nebulized epinephrine may be discharged home from the outpatient/ED/UC setting after a minimum of 2-3 hours if no stridor at rest.

Consider additional monitoring or evaluation prior to discharge in inpatients requiring repeated doses of racemic epinephrine after peak steroid effects (see algorithm)

Admit to Inpatient/ Observation

- Moderate severity despite treatment with corticosteroids
- Inadequate hydration
- Require supplemental oxygen and are proven not to be in acute or impending respiratory failure
- Condition deteriorates or does not improve with therapy
- Patients needing continued doses of racepinephrine after peak steroid effect
- Patients not otherwise meeting discharge criteria

Admit to ICU

- Severe or life-threatening severity
- Acute respiratory acidosis
- Bradypnea suggesting respiratory muscle fatigue and impending respiratory failure
- Lack of response to steroids and racemic epinephrine as characterized by persistent moderate-severe
 retractions, hypoxemia, severely decreased air entry, altered level of consciousness, difficulty feeding/talking, or
 difficulty controlling oral secretions



FOLLOW-UP | DISCHARGE INSTRUCTIONS

With PCP or designee as scheduled

If patient evaluated and discharged from the ED: PCP phone follow-up within 24 hours

If seen in PCP office: Parent/guardian to call back if patient worsens

If admitted: PCP phone follow-up within 12-24 hours of discharge and PCP office visit within 2 days.

Return Precautions

- Worsening increased work of breathing
- Lips or face turning blue
- Hoarse voice
- High fever, breathing fast, or fast heart beat
- Prolonged symptoms with no improvement of barking cough after 7 days

Note: If patients received multiple doses of steroids while hospitalized, consider more than one outpatient follow-up visit due to long half-life of dexamethasone.

EDUCATION

Parent | Caregiver Education

- Expected clinical course less than seven days
- · Educate to return for respiratory distress
- Smoking cessation counseling
- Provide parent with patient education materials

Knowledge Base

Viral croup is an acute inflammatory process in response to a viral infection that causes upper airway obstruction (primarily of the subglottic region) resulting in inspiratory stridor, barky cough and in more severe cases respiratory distress. Infection begins in the nasopharynx and spreads to the respiratory epithelium of larynx & trachea. Inflammation and edema of the vocal folds causes hoarseness.

Age: 6 months to 6 yrs (Mean = 18 mos)

Duration: 2 to 7 days

Morbidity: Highest first year of life

Epidemiology: Year round; most common fall and winter

ETIOLOGY OF CROUP

- Parainfluenza type 1(most common) 2, 3
- Influenza A & B



- Human metapneumovirus (hMPV)
- Respiratory syncytial virus (RSV)
- Rhinovirus
- SARS CoV-2
- Mycoplasma pneumoniae
- Enteroviruses
- Herpes Simplex viruses
- Adenovirus
- Measles virus



REFERENCES

- 1. Tyler A, Anderson L, Moss A, Graham J, Dempsey A, Carpenter T. Predictors of Symptom Rebound in Critically III Patients With Croup. Hospital Pediatrics. 2019;9(6):447-454.
- 2. Asmundsson AS, Arms J, Kaila R, et al. Hospital Course of Croup After Emergency Department Management. Hospital Pediatrics. 2019;9(5):326-332.
- 3. Smith DK, McDermott AJ, Sullivan JF. Croup: Diagnosis and Management. AFP. 2018;97(9):575-580.
- 4. Gates A, Johnson DW, Klassen TP. Glucocorticoids for Croup in Children. JAMA Pediatr. 2019;173(6):595.
- 5. Petrocheilou, A, Tanou, K, Kalampouka, E, Malakasioti, G, Ciannios, C, Kaditis, A. Viral Croup: Diagnosis and a Treatment Algorithm. Pediatric Pulmonlogy 2014; 49: 421-429.
- 6. Tyler A, McLeod L, Beaty B, et al. Variation in Inpatient Croup Management and Outcomes. Pediatrics. 2017;139(4):e20163582. doi:10.1542/peds.2016-3582
- 7. Ausejo M, Saenz A, Pham B, et al. The effectiveness of glucocorticoids in treating croup: meta-analysis. BMJ. 1999;319(7210):595-600. doi:10.1136/bmj.319.7210.595
- 8. Geelhoed G, Macdonald W. Oral and inhaled steroids in croup: a randomized, placebo-controlled trial. Pediatr Pulmonol 1995; 20: 355–61.
- 9. Geelhoed GC, Turner J, Macdonald WB. Efficacy of a small single dose of oral dexamethasone for outpatient croup: a double blind placebo controlled clinical trial [see comments]. BMJ 1996; 313: 140–2.
- 10. Klassen TP, Rowe PC. The croup score as an evaluative instrument in clinical trials. Arch Pediatr Adolesc Med 1995; 149: 60–1.
- 11. Jacobs S, Shortland G, Warner J, Dearden A, Gataure PS, Tarpey J. Validation of a croup score and its use in triaging children with croup. Anaesthesia 1994; 49: 903–6
- 12. Chan, A., J. Langley, et al. (2001). "Interobserver variability of croup scoring in clinical practice." <u>Paediatr Child</u> Health **6**(6): 347-351.
- 13. Brown, J.C., The management of croup. Br Med Bull, 2002. 61: p. 189-202.
- 14. Johnson DW. Croup. BMJ Clinical Evidence. 2009;2009:0321.
- 15. Kristjánsson S1, Berg-Kelly K .Inhalation of racemic adrenaline in the treatment of mild and moderately severe croup. Clinical symptom score and oxygen saturation measurements for evaluation of treatment effects. <u>Acta Paediatr.</u> 1994 Nov;83(11):1156-60.



CLINICAL IMPROVEMENT TEAM MEMBERS

Amy Tyler, MD | Hospitalist
Hannah Gardner, MD | Hospitalist
Jake Cripe, MD | Critical Care
Ryan Caltagirone, MD | Emergency Department
David Listman, MD | Emergency Department
Leigh Anne Bakel, MD | Hospitalist
Kaitlin Widmer, MD | Hospitalist
Melissa Scholes, MD | ENT

Grace Houser, MD | Pulmonology
Jason Child, MD | Infectious Disease
Hoke Stapp, MD | Primary Care Provider
Brian Bean, RT | Respiratory Therapy
Melissa Chaput, RT | Respiratory Therapy
Mollie Kempa, PharmD | Clinical Pharmacist
Katie DeGroat | Process Improvement
Liz Ficco | Clinical Pathway Coordinator

APPROVED BY

Pharmacy & Therapeutics Committee – October 7, 2021 Clinical Care Guideline and Measures Review Committee – September 27, 2021

MANUAL/DEPARTMENT	Clinical Pathways/Quality	
ORIGINATION DATE	August 11, 2011	
LAST DATE OF REVIEW OR REVISION	October 7, 2021	
COLORADO SPRINGS REVIEWED BY	Michael DiStefano, MD Chief Medical Officer, Colorado Springs	
APPROVED BY	Lalit Bajaj, MD, MPH Chief Quality Outcomes Officer	

REVIEW REVISION SCHEDULE

Scheduled for full review on October 7, 2025

Clinical pathways are intended for informational purposes only. They are current at the date of publication and are reviewed on a regular basis to align with the best available evidence. Some information and links may not be available to external viewers. External viewers are encouraged to consult other available sources if needed to confirm and supplement the content presented in the clinical pathways. Clinical pathways are not intended to take the place of a physician's or other health care provider's advice, and is not intended to diagnose, treat, cure or prevent any disease or other medical condition. The information should not be used in place of a visit, call, consultation or advice of a physician or other health care provider. Furthermore, the information is provided for use solely at your own risk. CHCO accepts no liability for the content, or for the consequences of any actions taken on the basis of the information provided. The information provided to you and the actions taken thereof are provided on an "as is" basis without any warranty of any kind, express or implied, from CHCO. CHCO declares no affiliation, sponsorship, nor any partnerships with any listed organization, or its respective directors, officers, employees, agents, contractors, affiliates, and representatives.



Discrimination is Against the Law. Children's Hospital Colorado complies with applicable Federal civil rights laws and does not discriminate on the basis of race, color, national origin, age, disability, or sex. Children's Hospital Colorado does not exclude people or treat them differently because of race, color, national origin, age, disability, or sex.

Children's Hospital Colorado provides free aids and services to people with disabilities to communicate effectively with us, such as: Qualified sign language interpreters, written information in other formats (large print, audio, accessible electronic formats, other formats). Children's Hospital Colorado provides free language services to people whose primary language is not English, such as: Qualified interpreters, information written in other languages.

If you need these services, contact the Medical Interpreters Department at 720.777.9800.

If you believe that Children's Hospital Colorado has failed to provide these services or discriminated in another way on the basis of race, color, national origin, age, disability, or sex, you can file a grievance with: Corporate Compliance Officer, 13123 E 16th Avenue, B450, Aurora, Colorado 80045, Phone: 720.777.1234, Fax: 720.777.7257, corporate. compliance@childrenscolorado.org. You can file a grievance in person or by mail, fax, or email. If you need help filing a grievance, the Corporate Compliance Officer is available to help you.

You can also file a civil rights complaint with the U.S. Department of Health and Human Services, Office for Civil Rights, electronically through the Office for Civil Rights Complaint Portal, available at ocrportal.hhs.gov/ocr/portal/lobby.jsf, or by mail or phone at: U.S. Department of Health and Human Services 200 Independence Avenue, SW Room 509F, HHH Building Washington, D.C. 20201 1-800-368-1019, 800-537-7697 (TDD) Complaint forms are available at www.hhs.gov/ocr/office/file/index.html.

Children's Hospital Colorado complies with applicable Federal civil rights laws and does not discriminate on the basis of race, color, national origin, age, disability, or sex.

ATENCIÓN: si habla español, tiene a su disposición servicios gratuitos de asistencia lingüística. Llame al 1-720-777-9800.

CHÚ Ý: Nếu bạn nói Tiếng Việt, có các dịch vụ hỗ trợ ngôn ngữ miễn phí dành cho bạn. Gọi số 1-720-777-9800. 주의: 한국어를 사용하시는 경우, 언어 지원 서비스를 무료로 이용하실 수 있습니다. 1-720-777-9800 번으로 전화해 주십시오

注意:如果您使用繁體中文,您可以免費獲得語言援助服務。請致電1-720-777-9800。

ВНИМАНИЕ: Если вы говорите на русском языке, то вам доступны бесплатные услуги перевода. Звоните 1-720-777-9800.

ማስታወሻ: የሚና7ሩት ቋንቋ ኣማርኛ ከሆነ የትርፖም እርዳታ ድርጅቶች፣ በነጻ ሊያግዝዎት ተዘጋጀተዋል፡ ወደ ሚከተለው ቁጥር ይደውሉ 1-720-777-9800 (መስማት ስተሳናቸው. رقم / 720-777-9800 ألغة بقال خدمات اللغوية تتوافر لك بالمجان. اتصل برقم 1-9800.

1 1 2011 1 1 2000 1 1 2011 1 2011 1 2011 1 2011 1 2011 1 2011 1 2011 1 2011 1 2011 1 2011 1 2011 1 2011 1 2011

ACHTUNG: Wenn Sie Deutsch sprechen, stehen Ihnen kostenlos sprachliche Hilfsdienstleistungen zur Verfügung. Rufnummer: 1-720-777-9800.

ATTENTION: Si vous parlez français, des services d'aide linguistique vous sont proposés gratuitement. Appelez le 1-720-777-9800.

ध्यान बनु होस्:तपाइले नेपाल बोल्नहन्छ भन तपाइको निमृत भाषा सहायता सवाहरू नःशल्क रूपमा उपलब्ध छ । फोन गनु होसर् 1-720-777-9800 ।

PAUNAWA: Kung nagsasalita ka ng Tagalog, maaari kang gumamit ng mga serbisyo ng tulong sa wika nang walang bayad. Tumawag sa 1-720-777-9800.

注意事項: 日本語を話される場合、無料の言語支援をご利用いただけます。1-720-777-9800まで、お電話にてご連絡ください。

Ntị: Q bụrụ na asụ Ibo, asụsụ aka ọasụ n'efu, defu, aka. Call 1-720-777-9800.